Media headlines about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cidara Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.5534782355119 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

A number of research analysts recently issued reports on the stock. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the company a “buy” rating in a report on Friday, January 19th. Zacks Investment Research cut shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Finally, HC Wainwright boosted their price objective on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Cidara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.93.

Shares of Cidara Therapeutics (NASDAQ CDTX) traded up $0.10 on Monday, reaching $6.50. 60,655 shares of the company’s stock were exchanged, compared to its average volume of 84,867. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.69 and a current ratio of 7.69. Cidara Therapeutics has a 1 year low of $5.60 and a 1 year high of $11.75. The company has a market capitalization of $130.54 and a price-to-earnings ratio of -1.92.

In related news, major shareholder Target N. V. Biotech purchased 60,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $7.57 per share, with a total value of $454,200.00. Following the completion of the purchase, the insider now owns 2,295,272 shares in the company, valued at approximately $17,375,209.04. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 18.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Cidara Therapeutics (CDTX) Getting Somewhat Positive Media Coverage, Accern Reports” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/12/cidara-therapeutics-cdtx-getting-somewhat-positive-media-coverage-accern-reports.html.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

Insider Buying and Selling by Quarter for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.